Market Closed -
Nasdaq
04:00:00 2024-05-17 pm EDT
|
5-day change
|
1st Jan Change
|
2.95
USD
|
+1.03%
|
|
+7.66%
|
-1.34%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
643.2
|
224.5
|
373.7
|
369.5
|
-
|
-
|
Enterprise Value (EV)
1 |
297.5
|
40.03
|
200.2
|
288.2
|
346.5
|
234.5
|
P/E ratio
|
-8.63
x
|
-3.91
x
|
-5.86
x
|
-4.15
x
|
-3.53
x
|
-3.31
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
1,809
x
|
29.7
x
|
8.97
x
|
EV / Revenue
|
-
|
-
|
-
|
1,410
x
|
27.9
x
|
5.69
x
|
EV / EBITDA
|
-7.16
x
|
-0.77
x
|
-3.22
x
|
-3.28
x
|
-3.77
x
|
-2.56
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
1.77
x
|
0.71
x
|
1.41
x
|
1.87
x
|
3.14
x
|
4.21
x
|
Nbr of stocks (in thousands)
|
124,167
|
124,724
|
124,969
|
125,265
|
-
|
-
|
Reference price
2 |
5.180
|
1.800
|
2.990
|
2.950
|
2.950
|
2.950
|
Announcement Date
|
2/24/22
|
2/23/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
0.2043
|
12.44
|
41.22
|
EBITDA
1 |
-
|
-41.54
|
-52.02
|
-62.17
|
-87.78
|
-92
|
-91.63
|
EBIT
1 |
-
|
-50.5
|
-63.62
|
-76.15
|
-95.16
|
-104.4
|
-104
|
Operating Margin
|
-
|
-
|
-
|
-
|
-46,573.31%
|
-839.35%
|
-252.39%
|
Earnings before Tax (EBT)
1 |
-
|
-50.32
|
-57.92
|
-63.68
|
-89.85
|
-107.6
|
-118.4
|
Net income
1 |
-15.62
|
-50.32
|
-57.92
|
-63.68
|
-89.85
|
-107.6
|
-118.4
|
Net margin
|
-
|
-
|
-
|
-
|
-43,972.98%
|
-864.65%
|
-287.26%
|
EPS
2 |
-
|
-0.6000
|
-0.4600
|
-0.5100
|
-0.7100
|
-0.8350
|
-0.8900
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/26/21
|
2/24/22
|
2/23/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.2043
|
1.088
|
2
|
EBITDA
1 |
-14.02
|
-13.63
|
-12.62
|
-12.64
|
-13.12
|
-14.82
|
-15.48
|
-15.5
|
-16.37
|
-17.98
|
-18.6
|
-20.3
|
-22.6
|
-21.8
|
-21.2
|
EBIT
1 |
-16.82
|
-16.02
|
-15.47
|
-15.82
|
-16.3
|
-18.06
|
-19.02
|
-19.08
|
-20
|
-21.61
|
-22.6
|
-24.57
|
-26.41
|
-25.1
|
-25.8
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-12,926.64%
|
-2,307.86%
|
-1,290%
|
Earnings before Tax (EBT)
1 |
-16.69
|
-15.76
|
-14.69
|
-14.06
|
-13.41
|
-14.96
|
-15.81
|
-15.88
|
-17.02
|
-18.73
|
-20.9
|
-23.2
|
-25.6
|
-28.3
|
-27.5
|
Net income
1 |
-16.69
|
-15.76
|
-14.69
|
-14.06
|
-13.41
|
-14.96
|
-15.81
|
-15.88
|
-17.02
|
-18.73
|
-20.9
|
-23.2
|
-25.6
|
-28.3
|
-27.5
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-12,528.75%
|
-2,602.3%
|
-1,375%
|
EPS
2 |
-0.1300
|
-0.1300
|
-0.1200
|
-0.1100
|
-0.1100
|
-0.1200
|
-0.1300
|
-0.1300
|
-0.1400
|
-0.1500
|
-0.1650
|
-0.1850
|
-0.2000
|
-0.2200
|
-0.2200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/3/22
|
8/2/22
|
11/1/22
|
2/23/23
|
5/2/23
|
8/2/23
|
10/31/23
|
2/28/24
|
4/30/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
346
|
184
|
173
|
81.3
|
23.1
|
135
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-30.1%
|
-17.1%
|
-21.9%
|
-36.8%
|
-64.5%
|
-63%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
2.920
|
2.520
|
2.120
|
1.580
|
0.9400
|
0.7000
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/26/21
|
2/24/22
|
2/23/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
2.95
USD Average target price
4.25
USD Spread / Average Target +44.07% Consensus |
1st Jan change
|
Capi.
|
---|
| -1.34% | 366M | | +33.63% | 50.85B | | -0.09% | 42.82B | | +49.62% | 42.03B | | -4.96% | 29.55B | | +11.18% | 26.11B | | -21.95% | 19.13B | | +8.61% | 13.05B | | +28.31% | 12.16B | | +24.73% | 12.08B |
Other Biotechnology & Medical Research
|